previous
character
murin
model
neurogen
bladder
dysfunct
induc
neurotrop
strain
coronaviru
present
studi
studi
role
longlast
neurodegener
develop
neurogen
bladder
dysfunct
mice
coronaviru
induc
enceph
cie
longterm
follow
studi
reveal
three
phenotyp
neurodegen
symptom
develop
recoveri
rec
group
chronic
progress
cpro
group
chronic
diseas
relapsingremit
episod
crelap
group
level
rec
group
crelap
group
cpro
group
diminish
brain
level
rec
group
cpro
group
also
diminish
urinari
bladder
mice
crelap
group
show
delay
recoveri
void
function
vitro
contractil
studi
determin
decreas
basal
detrusor
tone
reduc
amplitud
nervemedi
contract
crelap
group
wherea
cpro
group
elev
musclemedi
contract
conclus
mice
cie
develop
three
phenotyp
neurolog
impair
mimick
differ
type
ms
progress
human
show
differenti
mechan
drive
neurogen
bladder
dysfunct
neurogen
bladder
dysfunct
often
develop
patient
neurodegen
disord
multipl
sclerosi
ms
caus
great
discomfort
neg
effect
qualiti
individu
social
occup
sexual
life
patient
ms
experi
lower
urinari
tract
symptom
lut
includ
detrusor
overact
urgenc
frequenc
urin
nocturia
dysuria
preval
sever
lut
increas
diseas
durat
progress
physic
disabl
ms
patient
patient
bladder
symptom
present
onset
ms
may
demyelin
lesion
spinal
cord
andor
brain
detect
mri
common
symptom
report
patient
remiss
urgenc
micturit
follow
urinari
frequenc
bladder
symptom
becom
preval
patient
chronic
progress
diseas
often
accompani
bowel
sexual
dysfunct
poor
understand
mechan
underli
function
interplay
lower
urinari
tract
lut
nervou
system
warrant
translat
clinic
research
effort
field
experiment
autoimmun
encephalomyel
eae
one
studi
anim
model
ms
induc
inocul
rat
mice
antibodi
myelin
bind
protein
mbp
proteolipid
protein
plp
myelin
oligodendrocyt
glycoprotein
mog
inocul
anim
develop
patholog
featur
inflamm
demyelin
spinal
cord
brain
infiltr
spinal
statist
data
present
mean
se
result
statist
analyz
use
pair
ttest
compar
paramet
group
differ
time
point
unpair
ttest
compar
paramet
differ
group
systat
softwar
inc
san
jose
ca
data
p
differ
consid
statist
signific
cord
inflammatori
cell
express
proinflammatori
cytokin
eaedriven
demyelin
mostli
mediat
cell
phenotyp
popul
immun
cell
known
associ
sever
patholog
ms
sever
previou
studi
investig
micturit
abnorm
anim
eae
rat
mbpinduc
eae
detrusor
areflexia
detrusor
hyperact
observ
correl
spinal
cord
inflamm
hindlimb
paralysi
use
cystometr
analysi
mizusawa
et
al
show
eae
caus
detrusor
areflexia
femal
rat
comparison
develop
detrusor
overact
anoth
group
establish
major
femal
rat
show
symptom
detrusor
areflexia
prior
eae
onset
detrusor
overact
develop
onset
diseas
addit
anim
model
neurodegener
demyelin
includ
murin
model
coronavirusinduc
encephalomyel
cie
mice
inocul
neurotrop
strain
mous
hepat
viru
mhv
develop
cie
accompani
sever
central
nervou
system
cn
demyelin
axon
degener
viral
natur
cie
model
reflect
spontan
occur
demyelin
cn
comparison
induc
model
eg
eae
mhvdriven
demyelin
mediat
interferongamma
phenotyp
compel
preponder
cytokin
respons
previous
report
major
ms
patient
previous
character
symptom
neurogen
void
dysfunct
cie
mice
sever
neural
mechan
contribut
neurogen
bladder
cie
model
ms
identifi
laboratori
includ
morpholog
chang
neuron
center
control
micturit
activ
gliosi
lesion
site
spinal
cord
increas
express
proinflammatori
cytokin
acut
inflamm
cn
follow
upregul
antiinflammatori
cytokin
later
time
point
increas
purinerg
compon
nervemedi
bladder
contract
associ
chang
bladder
mucosa
chang
observ
within
month
inocul
viru
first
sign
demyelin
develop
cn
present
studi
aim
understand
longterm
effect
neurodegen
chang
void
pattern
bladder
function
cie
model
test
hypothesi
longlast
neurodegener
cie
mice
may
caus
develop
differenti
neurolog
phenotyp
ms
develop
associ
heterogen
type
neurogen
lut
longterm
followup
cie
mice
reveal
three
phenotyp
neurolog
symptom
develop
understand
effect
coronavirusinduc
demyelin
lut
function
perform
longterm
follow
studi
wk
cie
mice
describ
method
cie
mice
assign
one
follow
experiment
group
group
recoveri
initi
symptom
acut
phase
diseas
rec
group
group
chronic
progress
neurodegener
presenc
symptom
wk
postinocul
cpro
group
group
occur
relaps
remiss
episod
crelap
group
fig
mice
cie
group
anim
n
neurolog
impair
symptom
wk
therefor
assign
rec
group
fig
cie
mice
n
still
elev
clinic
symptom
score
css
assign
cpro
group
fig
cie
mice
n
experienc
relapsingremit
episod
therefor
assign
crelap
group
fig
inocul
mice
viru
caus
signific
weight
loss
wk
group
inocul
anim
fig
p
baselin
weight
loss
reflect
acut
phase
infect
associ
develop
activ
inflamm
cn
mice
group
start
gain
weight
normal
rate
wk
postinocul
analysi
combin
css
cie
mice
show
signific
neurolog
impair
develop
week
inocul
viru
fig
p
baselin
highest
weekli
record
css
reveal
mice
rec
cpro
group
css
cours
experi
fig
mice
cpro
group
show
pattern
neurolog
impair
similar
mice
rec
group
wk
howev
cpro
mice
still
css
respect
wk
postinocul
fig
interestingli
mice
crelap
group
wk
respect
css
earlier
time
point
compar
rec
cpro
mice
fig
longterm
followup
cie
mice
reveal
express
chang
cytokin
growth
factor
brain
urinari
bladder
group
previous
report
cie
mice
fluctuat
cn
cytokin
level
wk
postinocul
therefor
also
test
express
level
well
growth
factor
multiplex
elisa
wk
inocul
viru
rec
mice
significantli
decreas
express
level
brain
p
pb
group
fig
cpro
group
character
decreas
express
p
pb
group
fig
wherea
crelap
mice
significantli
reduc
level
brain
p
pb
group
signific
chang
cytokin
content
detect
spinal
cord
subgroup
cie
mice
data
shown
howev
sever
chang
note
urinari
bladder
cie
mice
figur
present
significantli
decreas
express
rec
mice
p
pb
group
reduc
content
urinari
bladder
cpro
mice
p
pb
group
without
substanti
chang
observ
crelap
group
fig
evalu
micturit
pattern
vivo
fpa
reveal
delay
recoveri
void
function
crelap
group
previous
report
increas
larg
cm
small
cm
void
spot
cie
mice
wk
inocul
viru
suggest
overact
bladder
phenotyp
develop
studi
follow
micturit
pattern
wk
rec
cpro
crelap
group
number
larg
urin
spot
crelap
group
significantli
higher
rec
group
wk
postinocul
fig
p
rec
cpro
group
addit
number
larg
urin
spot
crelap
group
wk
significantli
higher
number
wk
within
group
signific
differ
observ
number
small
urin
spot
group
longterm
followup
fig
mice
crelap
group
show
sever
overact
bladder
phenotyp
evalu
cystometri
fpa
assay
allow
longterm
followup
micturit
patter
mice
vivo
provid
direct
measur
bladder
pressur
bladder
capac
frequenc
micturit
therefor
perform
urodynam
evalu
void
pattern
subgroup
cie
mice
vivo
cystometri
conduct
unanesthet
mice
figur
show
repres
singl
micturit
cycl
record
control
pb
rec
cpro
crelap
group
mice
wk
postinocul
bladder
capac
fig
intermicturit
interv
fig
bladder
pressur
void
fig
group
except
crelap
group
similar
respect
valu
control
group
howev
mice
crelap
group
develop
overact
bladder
phenotyp
associ
lower
bladder
capac
vs
p
control
group
fig
reduc
ratio
normal
intermicturit
interv
p
ratio
control
group
fig
decreas
pressur
micturit
vs
ml
p
control
fig
result
suggest
mice
crelap
group
develop
sever
longlast
type
neurogen
bladder
overact
group
provid
evid
correl
type
neurodegen
chang
cn
type
develop
void
dysfunct
cie
mice
wwwnaturecomscientificreport
wwwnaturecomscientificreport
vitro
studi
reveal
differenti
contractil
respons
detrusor
electr
field
stimul
ef
among
cie
group
next
isol
urinari
bladder
cie
mice
measur
detrusor
muscl
tone
baselin
assess
peak
forc
pf
contractil
respons
ef
high
potassium
solut
pharmacolog
activ
differ
drug
vitro
contractil
studi
determin
decreas
basal
tone
detrusor
rec
group
p
fig
diminish
amplitud
nervemedi
contract
crelap
group
respons
ef
cpro
wwwnaturecomscientificreport
wwwnaturecomscientificreport
group
p
fig
bladder
smooth
muscl
strip
cpro
group
significantli
elev
contractil
respons
ef
control
p
fig
increas
pf
musclemedi
contract
respons
high
potassium
control
p
fig
addit
percentag
maxim
purinerg
respons
nervemedi
contract
normal
l
upregul
cpro
group
compar
control
group
p
fig
wherea
muscarin
respons
cpro
group
compar
control
group
fig
dissect
muscarin
compon
fig
nicotin
compon
fig
contractil
respons
ef
neither
reveal
signific
differ
experiment
group
evalu
veloc
contractil
relax
respons
applic
ef
calcul
contractil
relax
slope
purinerg
muscarin
muscarin
nicotin
nicotin
respons
purinerg
compon
bladder
smooth
muscl
strip
contract
cpro
mice
show
significantli
increas
slope
valu
contract
fig
e
relax
phase
fig
interestingli
purinerg
compon
detrusor
contractil
respons
crelap
group
mice
show
significantli
delay
relax
rate
evidenc
sr
slope
fig
j
wwwnaturecomscientificreport
wwwnaturecomscientificreport
longterm
followup
cie
mice
reveal
three
phenotyp
neurolog
symptom
develop
associ
heterogen
neurogen
bladder
dysfunct
symptom
neurodegen
chang
cie
mice
includ
wobbl
gait
hindlimb
paresi
quadriparesi
paralysi
previous
report
pattern
css
fluctuat
cie
mice
within
entir
period
observ
wk
use
assign
anim
one
follow
experiment
group
group
recoveri
initi
symptom
acut
phase
diseas
rec
group
chronic
group
progress
neurodegen
chang
cpro
group
chronic
group
relaps
remit
episod
crelap
group
subgroup
cie
mice
uniqu
featur
regard
bladder
function
assess
vitro
vivo
studi
type
neurodegen
symptom
observ
cie
mice
close
reflect
featur
symptom
progress
ms
patient
dysfunct
level
mobil
ms
vari
depend
stage
sever
diseas
base
recent
updat
classif
ms
phenotyp
human
cpro
subgroup
cie
mice
may
correspond
clinic
progress
type
human
ms
wherea
crelap
subgroup
reflect
relapsingremit
phenotyp
ms
patient
rec
subgroup
cie
mice
character
recoveri
initi
neurolog
impair
absenc
activ
css
correspond
type
ms
activ
could
still
progress
develop
sever
distinguish
clinic
phenotyp
progress
ms
symptom
patient
close
associ
degre
inflamm
cn
character
express
level
cytokin
growth
factor
phenotyp
neurolog
impair
bladder
dysfunct
observ
cie
mice
correl
function
modul
cytokin
growth
factor
cn
urinari
bladder
exampl
cpro
group
show
significantli
increas
bladder
compar
pb
mice
growth
factor
unchang
two
cie
subtyp
rec
crelap
group
along
known
coinhibitori
molecul
express
peripher
regulatori
immun
cell
popul
forkhead
box
regulatori
cell
treg
type
regulatori
cell
peripher
regulatori
immun
cell
express
andor
known
trigger
autoreact
cell
anergi
normal
condit
specul
upregul
urinari
bladder
cpro
group
may
reflect
inhibitori
feedback
loop
respons
continu
progress
neurolog
impair
present
crelap
rec
group
side
known
trigger
progress
ms
significantli
upregul
urinari
bladder
cpro
group
furthermor
crelap
cpro
group
chang
cytokin
content
brain
urinari
bladder
suggest
function
crosstalk
two
system
specul
support
previou
studi
establish
correl
function
connect
within
brain
region
void
behavior
ms
patient
therebi
provid
evid
relationship
pyramid
impair
lower
limb
sever
lut
ms
patient
underli
mechan
associ
still
unclear
could
partli
explain
somaticviscer
converg
neural
control
lower
limb
urinari
bladder
function
recent
studi
also
suggest
contribut
peripher
nervou
system
chang
viscer
organ
modul
lut
ms
patient
support
report
local
administr
lidocain
cannabinoid
urinari
bladder
ms
patient
neurogen
detrusor
overact
proven
therapeut
effect
improv
void
dysfunct
analys
bladder
function
fpa
cystometri
vivo
well
detrusor
contractil
organ
bath
studi
vitro
reveal
differenti
phenotyp
void
dysfunct
subgroup
cie
mice
mice
crelap
group
show
delay
recoveri
void
function
base
number
larg
void
spot
addit
vitro
contractil
studi
determin
decreas
basal
detrusor
tone
reduc
amplitud
nervemedi
contract
crelap
group
purinerg
respons
nervemedi
contract
upregul
crelap
group
data
provid
evid
anim
relapsingremit
type
neurodegen
chang
cn
sever
type
void
dysfunct
comparison
group
differ
type
bladder
dysfunct
cie
mice
suggest
anim
model
could
use
test
novel
therapeut
approach
treat
lut
base
degre
phenotyp
neurolog
impair
ms
patient
major
current
avail
wide
use
oral
medic
neurogen
bladder
dysfunct
includ
antimuscarin
agent
muscarin
receptor
wwwnaturecomscientificreport
wwwnaturecomscientificreport
predomin
express
urinari
bladder
subtyp
known
role
modul
bladder
reflex
howev
due
observ
upregul
purinerg
respons
crelap
group
downregul
muscarin
respons
cpro
group
convent
antimuscarin
agent
may
limit
effect
respect
group
ms
patient
although
purinerg
receptormedi
respons
urinari
bladder
ms
patient
anim
demyelin
previous
mention
littl
known
underli
mechan
one
public
show
purinerg
receptor
express
urinari
bladder
mice
eaedriven
demyelin
significantli
lower
control
mice
major
nicotin
subtyp
receptor
bladder
urothelium
particip
regul
bladder
excitatori
inhibitori
reflex
respect
therefor
signific
chang
slope
valu
relax
sr
respons
observ
crelap
group
may
explain
crelap
mice
show
irregular
atyp
pattern
micturit
cycl
reflect
fig
conclus
studi
identifi
sever
phenotyp
neurogen
bladder
dysfunct
base
pattern
neurolog
impair
develop
cie
mice
suggest
high
clinic
relev
viral
murin
model
human
ms
mechanist
differ
subgroup
cie
mice
make
model
suitabl
studi
relationship
void
dysfunct
progress
neurolog
impair
cours
virusinduc
demyelin
disord
test
novel
therapeut
approach
treatment
human
ms
studi
approv
studi
protocol
approv
institut
anim
care
use
committe
mhv
prepar
previous
describ
inocul
mice
observ
daili
evalu
neurolog
symptom
develop
use
clinic
symptom
score
css
system
weight
everi
week
wk
postinocul
clinic
symptom
score
css
assign
base
follow
scale
normal
clinic
sign
loss
tail
tonicitykyphosi
tail
paralysissever
kyphosi
partial
hindlimb
paralysi
complet
hindlimb
paralysi
complet
hindlimb
paralysi
forelimb
paresisparalysi
previous
describ
anim
weigh
inocul
baselin
everi
subsequ
week
experiment
end
point
mice
ad
libitum
access
food
water
special
measur
taken
accommod
neurolog
compromis
anim
inocul
viru
anim
observ
daili
week
evalu
degre
timedepend
neurolog
symptom
develop
grade
css
instil
mhv
degre
neurolog
impair
evalu
daili
css
previous
describ
follow
css
fluctuat
decid
group
anim
base
sever
durat
persistencerecoveri
neurolog
symptom
determin
css
fig
interest
group
anim
one
occur
relaps
remiss
episod
crelap
group
mimick
preval
phenotyp
ms
human
character
period
symptom
worsen
relaps
flareup
follow
period
recoveri
symptom
relaps
anim
assign
crelap
group
met
follow
criteria
presenc
symptomfre
period
least
hour
hr
recoveri
initi
rise
css
presenc
least
symptomfre
period
hr
durat
css
period
relaps
reoccurr
symptom
remiss
episod
anim
assign
recoveri
group
rec
chronic
progress
symptom
cpro
group
base
absenc
presenc
symptom
experiment
end
point
observ
relapsingremit
episod
algorithm
follow
assign
mous
one
describ
neurolog
group
present
fig
express
profil
cytokin
growth
factor
determin
multiplex
elisa
assay
total
protein
extract
frozen
brain
spinal
cord
urinari
bladder
tissu
use
radioimmunoprecipit
ripa
buffer
contain
proteas
phosphatas
inhibitor
cocktail
tissu
isol
experiment
end
point
week
postinocul
anim
assign
cystometri
group
multiplex
elisa
perform
quantibodi
custom
array
kit
qaacust
raybiotech
norcross
ga
accord
manufactur
instruct
panel
protein
load
incub
overnight
wash
wash
buffer
ii
detect
antibodi
cocktail
ad
well
incub
room
temperatur
rt
hour
wash
antistreptavidin
secondari
antibodi
licor
lincoln
ne
ad
incub
hour
rt
sampl
decant
wash
wash
buffer
five
time
minut
rt
micturit
pattern
evalu
filter
paper
assay
follow
micturit
pattern
vivo
anim
subject
filter
paper
assay
fpa
week
previous
describ
anim
place
individu
cage
contain
elev
inch
mesh
floor
h
filter
paper
filter
paper
qualit
advantec
tokyo
roshi
kaisha
ltd
japan
bottom
cage
mesh
mous
free
access
steril
water
gel
hydrogel
clear
westbrook
food
provid
test
everi
anim
underw
fpa
evalu
follow
time
point
preinocul
baselin
everi
week
wk
collect
filter
paper
imag
uv
light
labnet
dyna
uv
transillumin
labnet
wwwnaturecomscientificreport
wwwnaturecomscientificreport
intern
inc
edison
nj
digidocit
imag
system
uvp
cambridg
uk
digidocit
imag
softwar
uvp
cambridg
uk
number
larg
cm
small
cm
micturit
spot
sum
test
mous
urodynam
evalu
bladder
function
freeli
move
mice
anim
assign
urodynam
evalu
urinari
bladder
function
awak
cystometri
underw
surviv
surgic
procedur
insert
bladder
cathet
previous
describ
briefli
anim
anesthet
isofluoran
vedco
st
alban
vt
bladder
expos
lower
midlin
abdomin
incis
polyethylen
tube
id
mm
od
mm
intramed
becton
dickinson
parsippani
ny
flare
end
insert
punctur
bladder
dome
sutur
place
purs
string
sutur
silk
ethicon
somervil
nj
cathet
tunnel
subcutan
exterior
scapular
region
sutur
skin
fill
steril
salin
solut
confirm
leakag
bladder
cathet
plug
metal
rod
muscl
skin
layer
close
silk
sutur
ethicon
somervil
nj
particular
care
taken
stretch
bladder
procedur
restrict
normal
bladder
movement
cathet
place
mice
given
day
recov
surgeri
initi
cystometr
evalu
bladder
function
consciou
mice
place
cystometri
cage
length
cm
width
cm
height
cm
without
restraint
allow
acclim
min
tip
exterior
bladder
cathet
locat
base
mous
neck
connect
pressur
transduc
infus
pump
cystometri
station
small
anim
laboratori
cystometri
catamount
research
develop
st
alban
vt
use
tshape
valv
room
temperatur
salin
solut
nacl
infus
bladder
rate
void
urin
collect
tray
connect
forc
displac
transduc
integr
result
dataacquisit
program
anim
observ
approxim
six
eight
void
cycl
urodynam
paramet
continu
record
use
medcmg
small
anim
cystometri
acquisit
softwar
analyz
cystometri
data
analysi
softwar
v
catamount
research
develop
follow
cystometr
paramet
evalu
bladder
capac
pressur
start
micturit
micturit
rate
intraves
pressur
intermicturit
interv
present
ratio
cycl
durat
experiment
group
control
group
number
nonvoid
contract
nonvoid
contract
defin
increas
valu
detrusor
pressur
associ
void
equal
larger
twice
mean
valu
baselin
normal
void
contract
amplitud
least
third
maxim
pressur
singl
micturit
event
contractil
relax
detrusor
muscl
vitro
bladder
smooth
muscl
bsm
strip
isol
control
cie
mice
follow
previous
describ
procedur
briefli
murin
urinari
bladder
cut
half
place
individu
organ
bath
radnoti
llc
monrovia
ca
usa
contain
ml
normal
tyrod
buffer
tb
mm
nacl
kcl
cacl
mgcl
nah
po
nahco
glucos
ph
maintain
equilibr
constant
suppli
co
one
end
bladder
strip
attach
glass
rod
bottom
organ
chamber
end
attach
forc
displac
transduc
connect
computer
system
data
acquisit
analysi
ad
instrument
colorado
spring
co
usa
h
equilibr
length
optim
forc
develop
l
determin
manual
increas
length
strip
mm
increment
maxim
contractil
forc
respons
electr
field
stimul
ef
v
hz
ms
achiev
bath
solut
chang
fresh
tb
contain
drug
isol
cholinerg
purinerg
respons
ef
stimul
intact
bladder
stip
use
pharmacolog
evalu
avoid
desensitiv
cholinerg
purinerg
receptor
washoff
process
drug
follow
drug
combin
use
atropin
nonselect
machr
antagonist
sigma
st
loui
mo
nm
tmph
nicotin
antagonist
tocri
bioscienc
bristol
unit
kingdom
use
isol
purinerg
compon
contractil
respons
atp
purinerg
receptor
desensit
follow
paramet
measur
analyz
basal
muscl
tone
gg
g
forc
per
g
muscl
strip
weight
peak
forc
pf
g
gg
normal
weight
muscl
strip
integr
forc
maxim
slope
contract
sc
relax
sr
phase
previous
describ
